Navigation Links
Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
Date:3/20/2008

GRAND RAPIDS, Mich., March 20 /PRNewswire/ -- What happens when leading biochemists get together to challenge conventional pharmaceutical theories? Often, incredible new drug therapies are born. Recently, this same scenario began when two former major pharma scientists challenged the concept behind the leading treatments for type 2 diabetes, a disease that impacts millions of Americans. They saw the side effects caused by the current therapy like high blood pressure and weight gain, and went to work on a hypothesis that the current receptor was leading to these side effects associated with PPAR-based therapies.

As non-conventional as the theory was, it's working. Drs. Jerry Colca and Rolf Kletzien, co-founders of Kalamazoo, Michigan-based Metabolic Solutions Development Company (MSDC), have completed Phase I clinical studies and just received second phase funding from a Michigan-based science fund. They have applied for an FDA fast-track review of their work.

"We are pleased that our lead compound performed so well in Phase I studies," said Colca, MSDC's chief scientific officer. "Pre-clinical studies suggest that this compound can deliver significant pharmacological benefit without the complications inherent in current PPAR-based therapies."


'/>"/>
SOURCE Metabolic Solutions Development Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
8. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
9. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 03, 2015 Research and Markets ( ... "Global POC Diagnostics Market 2015-2019" report to their ... Global POC Diagnostics market to grow at a CAGR ... POC diagnostics are IVD devices and tools used ... setting. The use of these devices helps in the ...
(Date:3/3/2015)... 2015  Columbia Laboratories, Inc. (Nasdaq: CBRX ... a specialty pharmaceutical company focused on pharmaceuticals for women,s ... 27th Annual ROTH Conference, which will take place from ... Dana Point, California . Management,s presentation will ... Pacific Time (12:00 p.m. Eastern Time) in the Promenade ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of the "Global Ultrasound ... , The Global Ultrasound ... 5.79% over the period 2014-2019 Ultrasound ... sound waves. Ultrasound systems are extensively used by ...
Breaking Medicine Technology:Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2Global Ultrasound Equipment Market 2015-2019: Rise in Number of MI Diagnostic Procedures with GE Healthcare, Phillips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2
... and Safety of ,First Generation, Antisense, BERKELEY ... GNTA ) announced the presentation of new data ... can be safely administered in high doses by ... presented by Dr. Anthony Tolcher, Director,of Clinical Research, ...
... Improvement in Hemodynamics and Delay Disease Progression -, ... Inc.,today announced positive results from two trials demonstrating ... a combination therapy,for the treatment of pulmonary arterial ... when given in combination with sildenafil,is well-tolerated and ...
Cached Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 2Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 3
(Date:3/3/2015)... Ann Arbor, MI (PRWEB) March 03, 2015 ... on NPR News Morning Edition, science correspondent Shankar Vedantam ... the University of Pennsylvania about the drastic decrease in hand-hygiene ... shift. He suggested that the problem could be solved in ... to perform hand hygiene when they enter and exit a ...
(Date:3/3/2015)... 3, 2015) (PRWEB) March 03, 2015 ... an innovator in the travel industry for the past ... expansion plan. To fulfill his vision for the future ... 400 fun, exciting and well-compensated positions as travel sales ... news sales center planned for the Boynton Beach, Florida ...
(Date:3/3/2015)... Retrofit , the comprehensive weight ... corporations, today announces the appointment of its new chief ... Mary Pigatti has recruited technology, healthcare and ... for the fast-growing company, which was recently named one ... 2015. , “Retrofit is thrilled to announce this new ...
(Date:3/3/2015)... March 03, 2015 According to ... http://www.idataresearch.com ), market saturation has made neurosurgery navigation ... the United States. Unit sales growth moderately increased ... as facilities replace older systems, and as new ... market is very much a replacement and upgrade ...
(Date:3/3/2015)... MA (PRWEB) March 03, 2015 The ... transformed the science of the little-known and incurable disease, ... its #CureFSHD campaign . The purpose of the ... FSHD, one of the most common forms of muscular ... off the campaign, today the FSH Society will begin ...
Breaking Medicine News(10 mins):Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 2Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 3Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 2Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 2Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 4Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 2Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 3Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 2Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 3
... has had a fascinating journey and as they wrap up the ... Blues, it is time for introspection for Bobby Gillespie. The band's ... // ,But after that there was a time when their ... that the "heroin hell" kicked in and it was such a ...
... The exposed super model and ramp queen Kate Moss has ... about getting exposed by the media about her cocaine addiction. // ... Kate Moss is very close to him and he has known ... said to him that it made her face the reality and ...
... from the University of Melbourne and La Trobe University have ... grains such as wheat and barley. With the stress being ... that this discovery would allow them to manipulate the fibre ... the production of beta-glucans, which is a major part of ...
... go on Phase I trial. It maybe as early as ... Shaw. ,Ms.Shaw was speaking at the conference ... for innovation and R&D.// There are close to 34 million ... always bear this in mind and develop products accordingly. ...
... Briton underwent a successful life-changing operation in India and returned ... for being// overweight. ,David Rogers, 62, from Abbeydale, ... overweight for the double hip and knee replacements that he ... he was about 37 kg too heavy for the surgery. ...
... found with breast tumors can predict the outcomes of the ... appearing in he April 1 issue of Clinical Cancer Research, ... risk for an early relapse of breast cancer. ... a potential marker of relapse in hormone-receptor positive breast cancer ...
Cached Medicine News:Health News:Overweight Briton Underwent Successful Surgery In India Being Denied By NHS 2
... series SV stereomicroscopes are of ... to their mature modular design ... job in hand. This is ... demanding routine applications will appreciate, ...
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
10:1 Zoom Ratio - The parallel optical system of the SMZ-1000 has a 10:1 zoom with clickstops at 1X intervals. It features a zoom range of 0.8X to 8.0X and total magnification (depending on eyepieces...
Fixed Versatility - With a diverse selection of body tubes, stands, lighting techniques and Nikon's world-renowned optics, this modular microscope can be configured to fit nearly any application....
Medicine Products: